Brief Report: Increased technology use associated with lower A1C in a large pediatric clinical population by G. Todd Alonso (9568724)

“…</p> <p><strong>Results</strong><br> CGM use increased from 32.9% to 75.3%; HCL increased from 0.3% to 27.9%. Overall A1C decreased from 8.9% to 8.6% (p<0.0001). </p> <p><strong>Conclusions</strong></p> <p>Adoption of CGM and HCL was associated with decreased A1C, suggesting promotion of these technologies may yield glycemic benefits.…”

Lifespan of a single <i>T. utriculata</i> rosette. by Alexandra M. Campbell (3284094)

Random forest analysis showing discriminating biomarkers of diet-challenge in their decreasing orders of mean decrease accuracies (MDA). by Biswapriya B. Misra (563793)

Section A represents a randomised trial of IL6RA therapy with both normal IL-6 signalling and the effect of intervention. by Fergus W. Hamilton (10724401)

Realize large improvements in average NUE by removing low iNUE. by Newell R. Kitchen (12530448)

Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... by Elie Mulhem (22537863)

Summary estimate for the pooled PLR (A) and NLR (B) of MPV in the diagnosis of ITP. by Muluken Walle (13794209)

A graph showing risk of bias and applicability concerns among included studies. by Muluken Walle (13794209)

Procedures of sampling and measurements. by Xuegang Mao (599968)

Vertical distributions in the three field settings. by Xuegang Mao (599968)

Longer polyQ sequences decrease the transcriptional activity of AR. by Carlos M. Roggero (11909585)

Subjects:

Trajectory of the four analysed physiological parameters across the course of a confirmed COVID-19 infection centred around participant-reported symptom onset. by Kirsten Grossmann (10704657)

TMEM182 decreases OSCC cell motility. by En-Wei Hsing (154990)

Intracellular killing of <i>K</i>. <i>pneumoniae</i> mutants. by Estelle Ifrid (10076719)

Subjects:

K2 treatment increases access of a hydrophobic probe to the bacterial membrane of <i>K</i>. <i>pneumoniae</i>. by Estelle Ifrid (10076719)

Subjects:

K2 treatment renders <i>K</i>. <i>pneumoniae</i> more susceptible to intracellular killing. by Estelle Ifrid (10076719)

Subjects:

K2 increases the sensitivity of <i>K</i>. <i>pneumoniae</i> to polymyxin B. by Estelle Ifrid (10076719)

Subjects:

K2 is active at a concentration of 3 μM and above. by Estelle Ifrid (10076719)

Subjects:

K2 increases intracellular killing of <i>K</i>. <i>pneumoniae</i> by <i>kil1</i> KO and <i>kil2</i> KO cells. by Estelle Ifrid (10076719)

Subjects:

Three compounds affect the interaction between <i>K</i>. <i>pneumoniae</i> and phagocytic amoebae. by Estelle Ifrid (10076719)

Subjects: